BR112014009528A2 - métodos e composições para tratar eritropoiese ineficaz - Google Patents

métodos e composições para tratar eritropoiese ineficaz

Info

Publication number
BR112014009528A2
BR112014009528A2 BR112014009528A BR112014009528A BR112014009528A2 BR 112014009528 A2 BR112014009528 A2 BR 112014009528A2 BR 112014009528 A BR112014009528 A BR 112014009528A BR 112014009528 A BR112014009528 A BR 112014009528A BR 112014009528 A2 BR112014009528 A2 BR 112014009528A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
ineffective erythropoiesis
treating ineffective
treating
Prior art date
Application number
BR112014009528A
Other languages
English (en)
Other versions
BR112014009528B1 (pt
BR112014009528A8 (pt
Inventor
Seehra Jasbir
Venkata Sai Rajasekhar Suragani Naga
Kumar Ravindra
Scott Pearsall Robert
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority to BR122019023174-5A priority Critical patent/BR122019023174B1/pt
Priority to BR122019023166-4A priority patent/BR122019023166B1/pt
Publication of BR112014009528A2 publication Critical patent/BR112014009528A2/pt
Publication of BR112014009528A8 publication Critical patent/BR112014009528A8/pt
Publication of BR112014009528B1 publication Critical patent/BR112014009528B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112014009528-0A 2011-10-17 2012-10-17 usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz BR112014009528B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122019023174-5A BR122019023174B1 (pt) 2011-10-17 2012-10-17 Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia
BR122019023166-4A BR122019023166B1 (pt) 2011-10-17 2012-10-17 Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17
US61/547,932 2011-10-17
PCT/US2012/060650 WO2013059347A1 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis

Publications (3)

Publication Number Publication Date
BR112014009528A2 true BR112014009528A2 (pt) 2017-05-09
BR112014009528A8 BR112014009528A8 (pt) 2019-12-10
BR112014009528B1 BR112014009528B1 (pt) 2020-12-29

Family

ID=48141315

Family Applications (3)

Application Number Title Priority Date Filing Date
BR112014009528-0A BR112014009528B1 (pt) 2011-10-17 2012-10-17 usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
BR122019023166-4A BR122019023166B1 (pt) 2011-10-17 2012-10-17 Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose
BR122019023174-5A BR122019023174B1 (pt) 2011-10-17 2012-10-17 Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122019023166-4A BR122019023166B1 (pt) 2011-10-17 2012-10-17 Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose
BR122019023174-5A BR122019023174B1 (pt) 2011-10-17 2012-10-17 Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia

Country Status (13)

Country Link
US (4) US20130243743A1 (pt)
EP (3) EP3520805B1 (pt)
JP (4) JP6092883B2 (pt)
KR (4) KR20200019261A (pt)
CN (3) CN103987403B (pt)
AU (4) AU2012326207B2 (pt)
BR (3) BR112014009528B1 (pt)
CA (1) CA2852683A1 (pt)
DK (1) DK3520805T3 (pt)
EA (2) EA202090053A3 (pt)
ES (2) ES2741477T3 (pt)
HK (3) HK1203413A1 (pt)
WO (1) WO2013059347A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
DK3494986T3 (da) 2008-08-14 2020-08-03 Acceleron Pharma Inc GDF fanger
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP2475427B1 (en) * 2009-09-09 2016-11-30 Acceleron Pharma, Inc. Actriib antagonists and dosing and uses thereof
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
EP3808778A1 (en) * 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (en) * 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
MX2017013520A (es) 2015-04-22 2018-05-22 Alivegen Usa Inc Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
JP6976859B2 (ja) * 2015-05-13 2021-12-08 セルジーン コーポレイション ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
MA42160A (fr) 2015-05-20 2018-03-28 Maria Cappellini Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
CA3039525A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
WO2018231905A1 (en) 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2021518745A (ja) 2018-01-12 2021-08-05 ケロス セラピューティクス インコーポレイテッドＫｅｒｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アクチビンｉｉｂ型受容体変異体およびそれらの使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
CA2217545A1 (en) 1995-04-11 1996-10-17 Marc Vidal Reverse two-hybrid systems
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
EP1551385A4 (en) * 2002-10-15 2008-10-22 Celgene Corp SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3494986T3 (da) * 2008-08-14 2020-08-03 Acceleron Pharma Inc GDF fanger
CN113171442A (zh) * 2009-08-13 2021-07-27 阿塞勒隆制药公司 Gdf捕获物和***受体激活剂联合应用以增加红细胞水平

Also Published As

Publication number Publication date
HK1203413A1 (en) 2015-10-30
KR20200019261A (ko) 2020-02-21
ES2869168T3 (es) 2021-10-25
US20130243743A1 (en) 2013-09-19
BR122019023174B1 (pt) 2021-02-23
CN107693776A (zh) 2018-02-16
AU2017201580B2 (en) 2018-07-12
EP3520805B1 (en) 2021-03-10
EA202090053A3 (ru) 2020-06-30
US20170327800A1 (en) 2017-11-16
KR20220075438A (ko) 2022-06-08
HK1250341A1 (zh) 2018-12-14
JP2018165287A (ja) 2018-10-25
AU2020286229A1 (en) 2021-01-07
EP3875104A1 (en) 2021-09-08
EP2797620A1 (en) 2014-11-05
AU2012326207A1 (en) 2014-05-15
JP2014530253A (ja) 2014-11-17
BR112014009528B1 (pt) 2020-12-29
EP2797620A4 (en) 2015-05-20
WO2013059347A1 (en) 2013-04-25
EP2797620B1 (en) 2019-04-24
HK1252940A1 (zh) 2019-06-06
EP3520805A1 (en) 2019-08-07
JP2020186277A (ja) 2020-11-19
KR20140084211A (ko) 2014-07-04
DK3520805T3 (da) 2021-04-19
JP6092883B2 (ja) 2017-03-08
BR122019023166B1 (pt) 2021-02-23
US20170137791A1 (en) 2017-05-18
BR112014009528A8 (pt) 2019-12-10
CA2852683A1 (en) 2013-04-25
JP6796626B2 (ja) 2020-12-09
AU2018247262B2 (en) 2020-12-24
CN107837390A (zh) 2018-03-27
EA034563B1 (ru) 2020-02-20
EA201490809A1 (ru) 2014-09-30
AU2017201580A1 (en) 2017-03-30
EA202090053A2 (ru) 2020-04-30
ES2741477T3 (es) 2020-02-11
AU2018247262A1 (en) 2018-11-01
US20210207107A1 (en) 2021-07-08
AU2012326207B2 (en) 2016-12-15
KR102079482B1 (ko) 2020-02-19
CN103987403A (zh) 2014-08-13
JP2017101060A (ja) 2017-06-08
CN103987403B (zh) 2017-12-01
JP6383821B2 (ja) 2018-08-29
KR20190105113A (ko) 2019-09-11

Similar Documents

Publication Publication Date Title
BR112014009528A2 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
BR112013029813A2 (pt) métodos e dispositivos para distribuição de conteúdo
BR112014014234A2 (pt) composição não colorante para tratar as fibras queratínicas e método para tratar as fibras queratínicas
BR112014013246A8 (pt) composição catalisadora, e, método para tratar nox
EP2684167A4 (en) COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
BR112014016389A2 (pt) composições e métodos para o tratamento de doenças e distúrbios hepáticos
BR112013018679A2 (pt) agente para o tratamento da alopecia
CO6890100A2 (es) Tratamientos de combinación para hepatitis c
BR112014010450A2 (pt) composição e método
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
HK1207109A1 (en) Methods and compositions for treating amyloid deposits
BR112014022694A2 (pt) novos métodos e composições para o tratamento de doença
EP2713715A4 (en) COMPOSITIONS AND METHODS OF TREATING MATERIALS WITH INSECTICIDES AND POTENTRICULENT AGENTS
BR112014004414A2 (pt) composições e métodos para tratar doença neurodegenerativa
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BR112014012759A2 (pt) composto, composição e método para tratamento
BR112014010860A2 (pt) composição e método
BR112013019224A2 (pt) composição, e metodo
HK1211852A1 (en) Methods and compositions for treating progesterone-dependent conditions
BR112014010769A2 (pt) métodos e composições para neuroproteção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/10/2012, OBSERVADAS AS CONDICOES LEGAIS.